YD Bio (YDES) CEO Shen Ethan Buys 3,100 Shares

What Happened

• Dr. Shen Ethan, CEO and Director of YD Bio Ltd (YDES), made an open-market purchase of 3,100 ordinary shares on 2026-09-09. The filing reports a weighted average purchase price of $3.93 per share, for a total reported outlay of approximately $12,183. This was a buy (purchase) transaction.

Key Details

• Transaction date: 2026-09-09; Form 4 filed: 2026-09-10 (appears timely).
• Transaction type/code: Purchase (P) — open market or private purchase reported.
• Price(s): weighted average $3.93 per share; underlying trades occurred at prices ranging $3.80–$4.09 (footnote discloses multiple transaction prices).
• Shares acquired: 3,100 shares; total value ≈ $12,183.
• Shares owned after transaction: not disclosed in the information provided in this summary.
• Beneficial ownership note: reported shares are held by YD Biopharma Holding Limited, owned through E820N Assets Ltd. (BVI) and The E820N Trust; Dr. Shen is settlor, protector and sole beneficiary and is the beneficial owner (see footnote).
• Filing footnote commitment: reporting person will provide, on request, a breakdown of the number of shares purchased at each separate price within the $3.80–$4.09 range.

Context

• This was a direct purchase rather than an option exercise, award, or gift; purchases can be interpreted as an insider acquiring stock but do not, by themselves, prove a future business outcome. No late-filing flag was indicated in the provided data.